MMV 609
Alternative Names: MMV-1793609; MMV-609Latest Information Update: 02 Jan 2024
At a glance
- Originator Medicines for Malaria Venture; University of Kentucky
- Class Aminoquinolines; Antimalarials; Aza compounds; Benzimidazoles
- Mechanism of Action PfATP4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Malaria
Most Recent Events
- 22 Dec 2023 Preclinical trials in Malaria in Switzerland (unspecified route) (MMV pipeline, December 2023)
- 22 Dec 2023 Preclinical trials in Malaria in USA (unspecified route) (MMV pipeline, December 2023)
- 24 Mar 2021 Early research in Malaria in Switzerland, USA (IM) before March 2021 (Medicines for Malaria Venture pipeline, March 2021)